Skip to main content

Table 2 The 95% confidence intervals and P values of different parameters in the meta-analysis, meta-analysis without the case-control study, and Behr’s RCT

From: Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis

 

Meta-analysis

(Oral and Inhaled studies)

Meta-analysis

(Oral studies only)

Behr’s RCT

95% CI

(OR/SMD)

P values

95% CI

(OR/SMD)

P values

95% CI

(OR/SMD)

P values

SE

0.56–5.94

0.314

0.43–5.17

0.068

0.33–1.88

0.592

GI_SE

0.56–2.08

0.811

0.46–1.83

0.249

0.33–1.68

0.475

Skin_SE

0.77–4.71

0.162

0.74–4.88

0.611

1.14–77.52

0.038

Intole_SE

0.84–9.59

0.092

0.52–8.32

0.955

0.31–6.78

0.635

ΔFVC%

-0.86-0.69

0.693

NA

NA

−4.23-0.13

0.200

ΔDLco%

−0.34-0.62

0.580

NA

NA

−2.44-2.22

0.730

  1. Abbreviations: SE Side effect, GI_SE Gastrointestinal side effects, Intole_SE Intolerable side effects (leading to treatment discontinuation); ΔFVC%: decline in forced vital capacity percent predicted from treatment start to week 24; ΔDLco%: decline in diffusion capacity for carbon monoxide from treatment start to week 24